Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95cec123afa373b0980fecd8267c371a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_745a75b0350f49480798ef5ab913bc0a |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
filingDate |
2010-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0085edf91ae269f1fb72102c1217ff53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33be97c8c77f67870521a0618f6d6a94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b2a27ab1aa479ec337691b3c20e2dd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_144befc473f98683fe41d85090979120 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d9907378c4eb680adab576e6cc5a29b |
publicationDate |
2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20120012157-A |
titleOfInvention |
Pharmaceutical composition for the treatment and prevention of sepsis or septic shock containing cilostazol or a pharmacologically acceptable salt thereof as an active ingredient |
abstract |
The present invention relates to a pharmaceutical composition for treating or preventing pneumonia or sepsis shock containing cilostazol or a pharmacologically acceptable salt thereof as an active ingredient. The cilostazol or a pharmacologically acceptable salt thereof is already commercially available for other use to ensure stability, while pro-inflammatory cytokine production is inhibited in a concentration-dependent manner by blocking NF-κB and MAPK signaling pathways. Excessive systemic inflammatory response can be suppressed and can be usefully used as a medicament or food for treating or preventing sepsis or pulmonary shock by alleviating pathological changes in lung, kidney and liver in pulmonary or pulmonary septic shock. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101476349-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101347528-B1 |
priorityDate |
2010-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |